Loading
Veeva Systems Inc Stock: price and insider trades · United States
Veeva Systems Inc: what insiders have been doing
Veeva Systems Inc, founded in 2007, is a Healthcare & Pharma company based in Pleasanton, United States. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 101 filings came from 18 insiders.
Only sales appear on the open market, 16 sales in all totalling €14.6M, filed by 4 insiders. Biggest ticket of the year: €7.2M, sold by Schwenger Thomas D. and made public on 17 August 2026 (0.019% of market cap).
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 101 filings, this issuer sits above that mark. Our records for Veeva Systems Inc go back to 2016, with no purchases and 135 sales on the open market in total. The 10-K for the year ended 31 January 2026 shows 3.20 bn USD of revenue and 908.9 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
614
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€35M
135 ops. · all time
Who traded when
BuySaleThomas D. Schwenger12 sales
Jonathan Faddis7 sales
Hung Priscilla4 sales
Cabral Timothy S2 sales
Daniel J. Rizzo2 sales
Analyst consensus: bullish or bearish?
Analysts rate Veeva Systems Inc Buy (bullish), based on 27 analysts. Average price target: US$297.04.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,902 of 24,148 companies
60.1
score / 100
Value33
Quality87
FCF yld2.8%
Earn yld1.8%
EV/EBITDA52.8x
ROE14%
Gross mgn76%
Net mgn28%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended January 2026 · cache
US$297.35
Analyst consensus
27 analystsBuy
US$180.00Target US$297.04(-0%)US$343.00
Income statement
RevenueUS$3.2B
Gross profitUS$2.4B76% margin
EBITDAUS$954.3M30% margin
Net incomeUS$908.9M29.3% margin
Valuation
PER (trailing)49.5x
PER (forward)29.0x
P/Book6.5x
Beta0.93
Balance sheet & cash
Market capUS$48.1B
Total debtUS$95.9M
Free Cash FlowUS$1.4B
Debt / Equity2%
Profitability & ownership
ROE14.4%
ROA7.6%
% insiders8.6%
% institutions93.4%
Last declaration on 16 October 2026
Declarations614 total
3,515 shares@ US$300.1393Class A Common StockSEC:0001628280-26-066134:0
975 shares@ US$299.2928Class A Common StockSEC:0001628280-26-066134:1
708 shares@ US$298.1925Class A Common StockSEC:0001628280-26-066134:2
2,485 shares@ US$300.000.0015% mcap1.4% of flowCommonSEC144:0001950047-26-010240
3,000 shares@ US$300.000.0019% mcap1.7% of flowCommonSEC144:0001950047-26-010254
5,198 shares@ US$299.71530.0032% mcap32.1% of flowCommon StockSEC144:0001964306-26-000467
6,695 shares@ US$296.4150.0041% mcap3.9% of flowCommonSEC144:0001950047-26-010213
132,751 shares@ US$279.73340.082% mcap75.9% of flowCommonSEC144:0001950047-26-010046
1,272 shares@ US$281.930.0008% mcap1.6% of flowClass A Common StockSEC:0001628280-26-065015:1
2,181 shares0Class A Common StockSEC:0001628280-26-065022:0
1,636 shares0Class A Common StockSEC:0001628280-26-065019:0
1,672 shares0Class A Common StockSEC:0001628280-26-065011:0
168 shares0Class A Common StockSEC:0001628280-26-065005:0
1,636 shares0Class A Common StockSEC:0001628280-26-065002:0
803 shares0Class A Common StockSEC:0001628280-26-065002:2
1,110 shares@ US$281.930.0007% mcap10.7% of flowClass A Common StockSEC:0001628280-26-065022:1
705 shares@ US$281.930.0004% mcap51.2% of flowClass A Common StockSEC:0001628280-26-065019:1
2,907 shares0Class A Common StockSEC:0001628280-26-065015:0
854 shares@ US$281.930.0005% mcap15.1% of flowClass A Common StockSEC:0001628280-26-065011:1
4,520 shares@ US$276.53010.0028% mcap79.2% of flowClass A Common StockSEC:0001628280-26-065011:2
321 shares@ US$276.20650.0002% mcap5.6% of flowClass A Common StockSEC:0001628280-26-065011:3
61 shares@ US$281.930.0000% mcap9.1% of flowClass A Common StockSEC:0001628280-26-065005:1
833 shares@ US$281.930.0005% mcap7.0% of flowClass A Common StockSEC:0001628280-26-065002:1
4,841 shares@ US$276.50860.0029% mcap100.0% of flowCommonSEC144:0001950047-26-009996
1,000 shares@ US$265.200.0006% mcap1.2% of flowClass A Common StockSEC:0001628280-26-062233:0
25 of 614 declarations
About Veeva Systems Inc
Veeva Systems Inc. is a U.S.-based enterprise software company focused on cloud software, data, artificial intelligence, and consulting for the global life sciences industry. The company is listed in the United States on the NYSE under the ticker VEEV. It was founded in 2007, and its headquarters are in Pleasanton, California, United States.
Veeva’s business model is built around a vertical industry platform designed for the operational, regulatory, and commercial needs of pharmaceuticals, biotechnology companies, and other highly regulated life sciences organizations. Its core product stack spans Vault Platform, Vault CRM, Veeva Quality Cloud, Veeva Clinical, Veeva Regulatory, Veeva Safety, Veeva Medical, Veeva Commercial Cloud, and Veeva Data Cloud. More recently, the company has been pushing Veeva AI, a set of domain-specific AI capabilities and agents intended to work deeply inside Veeva applications. This is strategically important because Veeva is not selling generic software; it is offering workflow-heavy, compliance-aware applications tailored to the life sciences value chain.
Read moreShow less
From a competitive standpoint, Veeva holds a leading position in vertical cloud software for life sciences. Its moat is driven by industry specialization, long customer relationships, recurring subscription revenues, and the breadth of its platform, which extends from R&D and clinical operations to quality, regulatory, medical affairs, and commercial execution. In recent corporate communications, Veeva has highlighted the expansion of Vault CRM, growing adoption of Veeva Basics by emerging biotechs, and early momentum around AI-enabled products. That combination reinforces the company’s reputation as a mission-critical vendor rather than a discretionary IT provider.
Geographically, Veeva serves customers globally, with a commercial footprint and support capabilities across multiple regions, while maintaining its corporate base in California. Recent notable developments include the rollout of Veeva AI Agents across applications, new biotech-focused product introductions, collaboration announcements related to clinical-trial innovation, and strong quarterly results in 2025 and early 2026, supported by solid subscription revenue growth. For investors, Veeva stands out as a high-quality growth name in the Health & Pharma sector, with exposure to a structurally resilient end market and a differentiated software franchise built on deep domain expertise.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
